Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.